Dr. Dexter Cheung Appointed Chair of Technology Committee

NZX/ASX Announcement

23 September 2024

TruScreen Group Ltd Appoints Dr. Dexter Cheung as Chair of Technology Committee

TruScreen Group Ltd ("TruScreen" or "the Company") is pleased to announce the appointment of Dr. Dexter Cheung as Chair of the Company’s Technology Committee, effective immediately.

Dr. Cheung was appointed to the Board of TruScreen in March 2021 and is also a member of the Company’s Finance and Audit Committee. With over 20 years of experience as a medical device engineer and specialist in product research and development, Dr. Cheung brings significant expertise to assist the board in further developing the Company’s technology pathways.

Dr. Cheung is currently the Research and Development Manager for the respiratory humidification division of Fisher & Paykel Healthcare, a dual ASX/NZX-listed company. His extensive knowledge in manufacturing processes, product innovation, and medical device engineering, particularly in the field of opto-electronics, is highly relevant to TruScreen’s cervical cancer screening technology, which uses opto-electronic signatures for screening results. Dr. Cheung holds a PhD, Bachelor of Technology (Hons), and Master of Engineering.

The Board congratulates Dr. Cheung on his appointment and looks forward to his continued contribution to the Company.


This announcement has been approved by the Board.

ENDS

For more information, visit www.truscreen.com or contact:

Tony Ho
Chairman
[email protected]

Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF